Clinical trials: Toxic Shock Syndrome
Cytokine Release Syndrome, ICANS
Adjunctive Methylene Blue for Immunotherapy-related CRS and ICANS: Phase I Study
This Phase I, prospective, single-arm clinical study aims to evaluate the efficacy and safety of adjunctive methylene blue (MB) in patients experiencing cytokine release syndrome (CRS) or immune effector cell-associated…
- Trial name
- NCT07169487
- Testing
- Methylene Blue
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Toxic Shock Syndrome
Efficacy of IntraVenous ImmunoGlobulins in Toxic Shock Syndromes: a Paediatric Pilot Study
Staphylococcus aureus and Streptococcus pyogenes produce many virulence factors. Some of them are responsible for severe infections in humans. Superantigen toxins synthesized by S. aureus or by S.
- Trial name
- IVIG (NCT02219165)
- Testing
- Intravenous human immunoglobulin, Albumin
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Hospices Civils de Lyon
Streptococcal Sepsis, Invasive Group A Beta-Haemolytic Streptococcal Disease
Adjunctive Clindamycin Versus Linezolid for β-lactam Treated Patients With Invasive Group A Streptococcal Infections
This study aims to emulate a hypothetical target pragmatic multi-center, non-blinded trial of adult inpatients in the PINC AITM dataset with B-lactam treated culture confirmed monomicrobial invasive Group A streptococcus (GAS)…
- Conditions
- Streptococcal Sepsis, Invasive Group A Beta-Haemolytic Streptococcal Disease, Necrotizing Soft Tissue Infection, Infection, Bloodstream
- Trial name
- iGASAntitox (NCT06126263)
- Testing
- Linezolid, Clindamycin
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Staphylococcal Infection, Streptococcal Infection
Effectiveness of Intravenous Immunoglobulins (IVIG) in Toxic Shock Syndromes in Children
IGHN2 is an international, multicenter, double blind, randomized controlled trial aimed at assessing the efficacy on organ dysfunctions of Intravenous Immunoglobulins (IVIG) treatment in the acute phase of streptococcal or…
- Trial name
- IGHN2 (NCT02899702)
- Testing
- PRIVIGEN (CSL Behring), Albumin
- Where
- France
- Sponsor
- Hospices Civils de Lyon
Toxic Shock Syndrome Staphylococcal
Prodromes of Menstrual Staphylococcal Toxic Shock
Menstrual staphylococcal toxic shock is a rare but severe disease, requiring intensive care in over 80% of cases. Menstrual staphylococcal toxic shock develops during the peri-menstrual period, in healthy young women colonized by…
- Trial name
- IPro-CTSm (NCT06124599)
- Testing
- Identification of symptoms of menstrual staphylococcal toxic shock in last three menstrual period, Identification of symptoms of menstrual in control patient in the last three menstrual period
- Where
- France
- Volunteers
- 316 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Toxic Shock Syndrome
Clinical Trial of the BioMed rTSST-1 Variant Vaccine in Healthy Adults
Toxic Shock Syndrome (TSS) is a severe condition with high morbidity and mortality from the hosts overwhelming inflammatory response and cytokine storm. Staphylococcal superantigen toxins are the main causative agents.
- Trial name
- NCT02814708
- Testing
- rTSST-1v
- Where
- Austria
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Biomedizinische Forschungs gmbH
Severe Pediatric Infectious Shock
Pediatric Immune Response to Infectious Shock
Infectious shocks are associated with high mortality rates (20-40%). Anti-inflammatory strategies based on the postulate that mortality related to sepsis is mainly due to an overwhelming pro-inflammatory immune response have…
- Trial name
- PedIRIS (NCT02848144)
- Testing
- blood samples, Collection of nosocomial infections
- Where
- France
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Sepsis, Septic Shock
Strong Albumin Solutions in Patients With Septic Shock
Sepsis is an increasingly recognised burden to healthcare systems worldwide. Intravenous fluid therapy is a common first-line intervention recommended by international guidelines.
- Conditions
- Sepsis, Septic Shock, Shock, Toxic
- Trial name
- SWIPE2 (NCT05208242)
- Testing
- hyperoncotic human albumin solution, Buffered crystalloid solutions
- Where
- 2 sites in United Kingdom
- Volunteers
- 47 people
- Sponsor
- Manchester University NHS Foundation Trust
Toxic Shock Syndrome, Vaccination; Sepsis
rTSST-1 Variant Vaccine Phase 1 First-in-man Trail
Toxic Shock Syndrome (TSS) a severe condition with high morbidity and mortality results from the hosts overwhelming inflammatory response and cytokine storm. Staphylococcal superantigen toxins are the main causative agents.
- Trial name
- rTSST-1 (NCT02340338)
- Testing
- rTSST-1 Variant Candidate Vaccine
- Where
- Austria
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Biomedizinische Forschungs gmbH
Critical Illness, Antibiotic Toxicity
Target Attainment of TDM-guided Infusion of Piperacillin/Tazobactam and Cefepim in Critically Ill Patients
Although alternative dosing strategies can improve antimicrobial exposure in critically ill patients, the high PK variability in this population means that some may still receive sub-optimal antibiotic exposure leading to…
- Conditions
- Critical Illness, Antibiotic Toxicity, Sepsis, Septic Shock
- Trial name
- DOSATB (NCT04530045)
- Testing
- dosage of concentration of piperacillin and cefepim
- Where
- 2 sites in France
- Volunteers
- 99 people
- Sponsor
- Central Hospital, Nancy, France
Leukemia,Myeloid, Chronic, Leukemia,Myeloid,Philadelphia-Positive
Study Using Vaccination With Heat Shock Protein 70 (HSP70) for the Treatment of CML in Chronic Phase
Description: The trial is designed to determine the response of the immune system of patients with CML to a vaccine made from their own tumor.
- Trial name
- NCT00027144
- Testing
- Heat Shock Protein 70 HSP70
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Connecticut
Severe Hepatic Veno-Occlusive Disease
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
The purpose of this study is to (1) demonstrate the efficacy and safety (toxicity) of 25 mg/kg/day of Defibrotide in patients with severe veno-occlusive disease (sVOD) and (2) evaluate serum and endothelial markers of…
- Trial name
- NCT00358501
- Testing
- Defibrotide
- Where
- 25 sites in United States, Canada
- Volunteers
- 134 people
- Sponsor
- Jazz Pharmaceuticals
B-Acute Lymphoblastic Leukemia, CAR-T Cell Therapy
Pre-emptive Anakinra for Cytokine Event Reduction
Objectives: The primary objective of this study will be to evaluate the impact of pre-emptive use of anakinra on the rate of severe cytokine release syndrome (CRS) following CD19-directed chimeric antigen receptor (CAR) T-cell…
- Conditions
- B-Acute Lymphoblastic Leukemia, CAR-T Cell Therapy, Cytokine Release Syndrome, Immune Effector Cell Associated Neurotoxicity Syndrome
- Trial name
- PACER (NCT06703216)
- Testing
- Anakinra (Kineret®)
- Where
- United States
- Sponsor
- Kevin McNerney
Toxic-Shock Syndrome, Sepsis
Amendment of rTSST-1 Variant Vaccine Phase 1 Clinical Trial
Toxic Shock Syndrome (TSS) a severe condition with high morbidity and mortality results from the hosts overwhelming inflammatory response and cytokine storm. Staphylococcal superantigen toxins are the main causative agents.
- Trial name
- NCT02971670
- Testing
- rTSST-1 Variant Candidate Vaccine
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Biomedizinische Forschungs gmbH
Sepsis, Septic Shock
Aminoglycoside Administration in Septic Patients
Sepsis is one of the main causes of mortality and morbidity in an ICU setting, while the responsible microorganisms most frequently isolated are multidrug-resistant gram-negative bacteria.
- Conditions
- Sepsis, Septic Shock, Aminoglycoside Toxicity, Renal Replacement Therapy
- Trial name
- AMASEP (NCT06226441)
- Testing
- Continuous Renal Replacement Therapy
- Where
- Greece
- Volunteers
- 50 people
- Sponsor
- University of Thessaly
Preterm Birth, Premature
Comparison of the Acute Effects of Chest Physiotherapy Methods Applied in Different Positions in Preterm Newborns
Infants in the neonatal intensive care unit (NICU) may be lost due to risks such as being sensitive, frequent exposure to birth complications and being prone to infection.
- Conditions
- Preterm Birth, Premature, Bronchopulmonary Dysplasia, Respiratory Distress Syndrome
- Trial name
- therapy (NCT05036603)
- Testing
- chest physiotherapy
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Sanko University
Cytokine Release Syndrome, Neoplasms
Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse Event
Background: Drugs or cell therapies to treat cancer can sometimes cause cytokine release syndrome (CRS). That is, the body makes too many cytokines after treatment. Cytokines are proteins that play a role in the immune system.
- Conditions
- Cytokine Release Syndrome, Neoplasms, Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Trial name
- NCT07499128
- Testing
- TempTraq, VitalTraq
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
This is a phase II study to evaluate the outpatient administration of Teclistamab or Talquetamab in Multiple Myeloma patients
- Trial name
- NCT05972135
- Testing
- Teclistamab, Talquetamab, Tocilizumab
- Where
- 17 sites in United States
- Volunteers
- 100 people
- Sponsor
- SCRI Development Innovations, LLC
Sexual Transmitted Disease, Vaginosis, Bacterial
Impact of Internal Menstrual Protections on Immunity and Vaginal Microbiota
The availability, effectiveness, and safety of menstrual protection represent a key public health issue. However, research on women's menstrual and sexual health remains extremely limited.
- Conditions
- Sexual Transmitted Disease, Vaginosis, Bacterial, Mycosis, Urogenital Disease
- Trial name
- CUPS2 (NCT07199998)
- Testing
- Samples collection (whole blood, urine, vaginal and cervical cells)
- Where
- France
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Centre National de la Recherche Scientifique, France
Inflammatory Response, Multi Organ Failure
Association of Cytokines With the Development of Complications in Burn and Toxic Epidermal Necrolysis (TENS) Patients
This study will involve blood draws to test for specific cytokines. The study goal is to gain a better understanding of the role of inflammatory response in the development of specific complications in burn and TENS patients.
- Conditions
- Inflammatory Response, Multi Organ Failure, Nosocomial Infection, Deep Vein Thrombosis
- Trial name
- NCT04252651
- Testing
- Blood Draw
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Joseph M. Still Research Foundation, Inc.